‘K-Medical Device’ winning 1st place in Malaysian Oncology Society paper

AdipoLABs, “We have proven the effectiveness of the product’s ‘cancer immunotherapy’ through ASCOMOS”

ASCOMOS Thesis Poster Category Grand Prize Award Ceremony. A paper on hyperthermia cancer treatment in which Dr. Cheong E Von and others participated took first place/Photo provided by AdipoLABs

At the recently held ‘Malaysian Society of Oncology Annual Conference’ (ASCOMOS), a paper using Korean medical device took first place.

The medical device is ‘REMISSION 1℃’, a high-frequency-based hyperthermia cancer treatment device. Developer AdipoLABs (CEO Han Sung-ho) said, "The academic conference 'ASCOMOS' is a large-scale academic conference held every year in Malaysia under the banner of 'high-level expansion of oncology and through the paper that won first place, ' REMISSION 1℃' has been proven to be effective in treating cancer, relieving pain, and treating immunity.”

The '34th Annual Academic Conference of the Malaysian Oncology Society' was held at the Sabah International Convention Center in Malaysia with the participation of about 200 local oncology medical staff. About 20 hospitals published papers related to cancer treatment this time. Among these, a paper on the topic of 'hyperthermia therapy for the treatment of patients with painful and unresectable malignant tumors of the abdomen or pelvis' took first place. This is a thesis by Dr. Ho Gwo Fuang and Dr. Cheong E Von from the University Hospital of Malaysia (UMMC), and it contains content that proves the effectiveness of ' REMISSION 1℃'.

An official from AdipoLABs said, “The paper evaluated the effect of hyperthermia, which is used as an adjuvant therapy for standard tumor treatment, on pain scores, quality of life, and immune response,” and added, “It was found that hyperthermia improved pain in patients with advanced malignant tumors.” “It is described as beneficial,” he said. He also added, "It also contains information that heat cancer treatment appears to be promising for changes in immune response. This can be seen as a paper confirming the role of 'hyperthermia therapy' in cancer immunotherapy."

Malaysian Minister of Community Development and People's Welfare (KPMKR) Datuk James Ratib, who attended the conference, said, "Sabah's first hyperthermia treatment is a big step forward in creating better health and greater hope for cancer patients in the region." “We celebrate this new frontier in medicine that can yield promising results for difficult diseases such as cancer.”

Prior to this academic conference, AdipoLABs supplied the high-frequency hyperthermia cancer treatment device 'REMISSION 1℃' to the University Hospital of Malaysia (UMMC) in 2019 for clinical purposes. According to the company, 'Ho Gwo Fuang', a member of the hospital, is a renowned cancer treatment specialist who has been active globally. He has been treating about 200 cancer patients in his country using ' REMISSION 1℃', and the details of its clinical application were revealed at an academic conference. ' REMISSION 1℃' received approval from the Ministry of Food and Drug Safety in 2015 for manufacturing high-frequency medical heaters for cancer treatment. Domestic general hospitals, including Seoul St. Mary's Hospital, and oriental medicine along with nursing hospitals have adopted this device.

Han Sung-ho, CEO of AdipoLABs, said, “We hope that the results of this clinical trial will provide hope to many cancer patients around the world.” He added, “We will prove the effectiveness of REMISSION 1℃ for cancer treatment in India, China, and other countries. We are raising the status of Korea’s medical devices to the world.”

출처: https://news.mt.co.kr/mtview.php?no=2023101614441230913&type=1